Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

Table 1 Sensitivity of commercial CCP2 test and noncommercial CFFCP enzyme-linked immunosorbent assays in different rheumatoid arthritis populations and control groups

Population	n	CFFCP1	CFFCP2	CFFCP3	CCP2
Rheumatoid arthritis	322	232 (72%)	251 (78%)	230 (71.4%)	238 (73.9%)
RF⁺	226	188 (83.2%)	199 (88.1%)	192 (85%)	199 (88.1%)
RF^-a	95	43 (45.3%)	52 (54.7%)	38 (40%)	39 (41.1%)
Early	134	102 (76.1%)	104 (77.6%)	99 (73.9%)	99 (73.9%)
Anti-TNF-α treatment	78	56 (71.8%)	62 (79.5%)	61 (78.2%)	62 (79.5%)
Healthy blood donors	307	6 (2%)	6 (2%)	6 (2%)	6 (2%)
Systemic lupus erythematosus	119	11 (9.2%)	11 (9.2%)	9 (7.6%)	9 (7.6%)
Psoriatic arthritis	133	6 (4.5%)	13 (9.8%)	2 (1.5%)	4 (3%)
Hepatitis C virus infection	84	12 (14.3%)	2 (2.4%)	2 (2.4%)	1 (1.2%)

^aP < 0.0001 for all autoantibodies in comparison with RF+ rheumatoid arthritis. In one RA patient, RF status was not available. RF = rheumatoid factor; TNF = tumor necrosis factor.